Methyl 2,5-dihydroxycinnamate

Discontinued Product

0577 has been discontinued.

View all EGFR products.
说明: EGFR-kinase inhibitor
别名: Erbstatin analog
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for Methyl 2,5-dihydroxycinnamate

Methyl 2,5-dihydroxycinnamate is an erbstatin analog. Inhibitor of EGF receptor-associated tyrosine kinases.

技术数据 for Methyl 2,5-dihydroxycinnamate

分子量 194.19
公式 C10H10O4
储存 Store at RT
纯度 ≥98% (HPLC)
CAS Number 63177-57-1
PubChem ID 5353609
InChI Key BQCNSTFWSKOWMA-GORDUTHDSA-N
Smiles COC(=O)\C=C\C1=C(O)C=CC(O)=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Methyl 2,5-dihydroxycinnamate

参考文献 for Methyl 2,5-dihydroxycinnamate

参考文献是支持产品生物活性的出版物。

Isshiki et al (1990) Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 260 198 PMID: 2298299

按产品操作查看相关产品

查看全部 EGFR Inhibitors

关键词: Methyl 2,5-dihydroxycinnamate, Methyl 2,5-dihydroxycinnamate supplier, EGFR, kinase, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, ErbB, Her, RTK, Receptor, Tyrosine, Kinases, RTKs, Methyl-25-dihydroxycinnamate, Erbstatin, analog, 0577, Tocris Bioscience

篇 Methyl 2,5-dihydroxycinnamate 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Methyl 2,5-dihydroxycinnamate 的引用文献。

Methyl 2,5-dihydroxycinnamate 的评论

目前没有该产品的评论。 Be the first to review Methyl 2,5-dihydroxycinnamate and earn rewards!

Have you used Methyl 2,5-dihydroxycinnamate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.